GlassScriptPhysician profile
Alan Michael Wilimitis
NPI 1972603207
$1,274.69
in general payments reported to CMS, 2019-2025
14 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical Adolescent Medicine (Pediatrics) provider received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $167 · 2021: $291 · 2022: $121 · 2023: $241 · 2024: $134 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $548.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $257.51 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Glaxosmithkline, LLC. | $228.34 | 2019-2025 | Bexsero, Pediarix |
| Sanofi Pasteur INC. | $129.02 | 2019-2025 | |
| Kaleo, INC. | $120.54 | 2020-2023 | Auvi-Q |
| Seqirus USA INC | $118.98 | 2021-2025 | Flucelvax, Flucelvax Quadrivalent |
| Takeda Pharmaceuticals U.S.A., INC. | $110.86 | 2019-2021 | |
| Cranial Technologies, INC | $109.82 | 2019-2025 | Doc Band |
| Pfizer INC. | $52.98 | 2021-2023 | |
| Collegium Pharmaceutical, INC. | $40.69 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $30.57 | 2020-2021 | |
| Genentech USA, INC. | $26.48 | 2021 | |
| Ironshore Pharmaceuticals INC. | $18.13 | 2019 | |
| Tris Pharma INC | $16.19 | 2025 | Dyanavel Xr |
| Neurelis, INC. | $14.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Wilimitis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.